Ruzsics Zsolt, Hoffmann Katja, Riedl André, Krawczyk Adalbert, Widera Marek, Sertznig Helene, Schipper Leonie, Kapper-Falcone Valeria, Debreczeny Monika, Ernst Wolfgang, Grabherr Reingard, Hengel Hartmut, Harant Hanna
Institute of Virology, Medical Center-University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Front Microbiol. 2020 Nov 17;11:601555. doi: 10.3389/fmicb.2020.601555. eCollection 2020.
Viral infections are a global disease burden with only a limited number of antiviral agents available. Due to newly emerging viral pathogens and increasing occurrence of drug resistance, there is a continuous need for additional therapeutic options, preferably with extended target range. In the present study, we describe a novel antiviral peptide with broad activity against several double-stranded DNA viruses. The 22-mer peptide TAT-I24 potently neutralized viruses such as herpes simplex viruses, adenovirus type 5, cytomegalovirus, vaccinia virus, and simian virus 40 in cell culture models, while being less active against RNA viruses. The peptide TAT-I24 therefore represents a novel and promising drug candidate for use against double-stranded DNA viruses.
病毒感染是一种全球性的疾病负担,而可用的抗病毒药物数量有限。由于新出现的病毒病原体以及耐药性的不断增加,持续需要更多的治疗选择,最好是具有更广泛的靶点范围。在本研究中,我们描述了一种对几种双链DNA病毒具有广泛活性的新型抗病毒肽。22肽TAT-I24在细胞培养模型中能有效中和单纯疱疹病毒、5型腺病毒、巨细胞病毒、痘苗病毒和猿猴病毒40等病毒,而对RNA病毒的活性较低。因此,肽TAT-I24是一种用于对抗双链DNA病毒的新型且有前景的候选药物。